Recent 8-K filings for KNSA

• May 29, 2026, 4:35 PM ET other materiality 0.15 neutral item 5.07 ◈ Shareholder Votes ×8

  Kiniksa shareholders re-elect all three Class II directors and approve all eight proposals at 2026 annual meeting

  Stephen R. Biggar re-elected with 37.5M for, 12.0M against; G. Bradley Cole and Barry D. Quart each received ~48.3M for.

• May 26, 2026, 4:55 PM ET other material materiality 0.60 neutral item 1.01item 9.01

  Kiniksa caps Baker Bros. voting power at 49.9% by waiving conversion rights

  Baker Bros. entities hold 12.78M A1 and 16.06M B1 shares; they waive conversion into A/B shares if ownership exceeds 49.9% voting rights.

• May 1, 2026, 7:59 PM ET leadership materiality 0.35 neutral item 5.02 ◈ executive_change ×2

  Kiniksa CSO Eben Tessari resigns, signs consulting deal at $450/hr

  Eben Tessari resigned as Chief Strategy Officer effective May 15, 2026, to take another life-sciences executive role.

• April 28, 2026, 7:59 PM ET earnings materiality 0.90 positive item 2.02item 9.01 ◈ Earnings Releases

  Kiniksa Reports Q1 2026 ARCALYST Revenue of $214.3M, Raises 2026 Guidance to $930-$945M

  ARCALYST Q1 2026 net product revenue $214.3 million, representing 56% year-over-year growth.

• February 24, 2026, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Kiniksa reports Q4/FY 2025 net income; ARCALYST revenue up 62% to $677.6M; guides 2026 $900-920M

  ARCALYST net product revenue $202.1M Q4, $677.6M FY 2025 (+62% YoY); gross-to-net improved to 8.4%.

• January 14, 2026, 6:59 PM ET leadership materiality 0.60 neutral item 5.02

  Kiniksa appoints Ross Moat as COO and Eben Tessari as Chief Strategy Officer

  Ross Moat promoted to COO effective Jan 10, 2026; will oversee commercial and functional operations.

• January 12, 2026, 6:59 PM ET other material materiality 0.75 positive item 2.02item 9.01

  Kiniksa 2025 ARCALYST revenue $677.5M (+62% YoY), guides 2026 to $900-920M

  ARCALYST net product revenue $677.5M in 2025, up ~62% YoY from $417.0M in 2024.

• October 28, 2025, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  Kiniksa Q3 ARCALYST revenue $180.9M (+61% YoY); raises 2025 guidance to $670-675M

  Net income $18.4M (vs loss $12.7M); cash $352.1M, no debt.

• September 3, 2025, 7:59 PM ET other material materiality 0.10 neutral item 7.01item 9.01

  Kiniksa posts September 2025 investor presentation, no material new information disclosed

  Investor presentation posted on investors.kiniksa.com on September 3, 2025.

• July 29, 2025, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  Kiniksa Q2 ARCALYST revenue $156.8M (+52% YoY); raises 2025 guidance to $625-640M

  ARCALYST net product revenue $156.8M in Q2 2025, up 52% from $103.4M in Q2 2024 (excl. $5.2M license revenue).

• June 5, 2025, 7:59 PM ET other material materiality 0.40 neutral item 7.01item 9.01

  Kiniksa details Phase 2/3 trial design for KPL-387 in recurrent pericarditis; initiation mid-2025

  Phase 2/3 trial: dose-focusing portion enrolls up to ~80 patients; pivotal portion up to ~85.

• June 3, 2025, 7:59 PM ET other material materiality 0.15 neutral item 5.07

  Kiniksa shareholders elect all director nominees and approve all 13 proposals at annual meeting

  All 10 director nominees elected; Stephen R. Biggar received 15.3M against votes, Felix J. Baker 12.3M against.

• April 29, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Kiniksa Q1 2025 ARCALYST revenue $137.8M (+75% YoY); guides FY 2025 to $590-605M

  ARCALYST net product revenue $137.8M in Q1 2025, up 75% YoY; net income $8.5M vs loss of $17.7M in Q1 2024.

• April 23, 2025, 7:59 PM ET other material materiality 0.55 neutral item 5.02item 9.01

  Kiniksa approves KPL-387 LTIP for execs, grants PSUs and options tied to BLA submission and FDA approval

  Compensation Committee approved KPL-387 Long-Term Incentive Plan for executive officers, linked to BLA submission (Milestone 1) and FDA approval (Milestone 2) for recurrent pericarditis treatment.

• February 25, 2025, 6:59 PM ET earnings materiality 0.75 neutral item 1.02item 2.02item 2.05item 9.01

  Kiniksa Q4 ARCALYST rev $122.5M ($417M FY); guides 2025 $560-580M; discontinues mavrilimumab & abiprubart

  ARCALYST Q4 net product revenue $122.5M; full year $417.0M (79% YoY growth).

• January 13, 2025, 6:59 PM ET other material materiality 0.80 positive item 2.02item 9.01

  Kiniksa reports 2024 ARCALYST net product revenue $416.4M (+79% YoY); guides 2025 to $560-580M

  ARCALYST net product revenue: Q4 2024 $121.9M, FY 2024 $416.4M (unaudited), ~79% YoY growth.

• October 29, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Kiniksa Q3 ARCALYST revenue $112.2M (+73% YoY); FY guidance raised to $410-420M

  ARCALYST Q3 net product revenue $112.2M, up 73% YoY; FY 2024 guidance raised to $410-420M from $405-415M.

• October 7, 2024, 7:59 PM ET leadership materiality 0.30 neutral item 5.02 ◈ executive_change

  Kiniksa appoints M. Cantey Boyd to Board, increasing size to 10 directors

  Board size increased from 9 to 10; Boyd appointed as Class III director.

• July 23, 2024, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  Kiniksa Q2 ARCALYST revenue $103.4M (+90% YoY); 2024 guidance raised to $405-415M

  ARCALYST net product revenue $103.4M in Q2 2024, up 90% YoY; ~11% of target 14,000 patients on therapy.

• June 28, 2024, 7:59 PM ET other material materiality 0.70 neutral item 1.01item 3.01item 3.02item 3.03item 5.03item 5.02item 8.01item 9.01

  Kiniksa completes redomiciliation from Bermuda to UK, shares trade on Nasdaq under same symbol KNSA

  Effective June 27, 2024, Kiniksa redomiciled to UK via Bermuda court-approved scheme of arrangement.

• June 25, 2024, 7:59 PM ET other material materiality 0.60 neutral item 1.01item 9.01

  Kiniksa signs manufacturing agreement with Samsung Biologics for ARCALYST

  Wholly-owned subsidiary entered MSA and PSA with Samsung Biologics for ARCALYST (rilonacept) drug substance.

• June 14, 2024, 7:59 PM ET other material materiality 0.50 neutral item 8.01

  Kiniksa gets Bermuda court sanction for redomiciliation to UK, effective ~June 27

  Bermuda Supreme Court sanctioned the scheme of arrangement on June 14, 2024.

• June 5, 2024, 7:59 PM ET other material materiality 0.15 neutral item 5.07

  Kiniksa shareholders approve redomiciliation scheme; court sanction hearing set for June 14

  Scheme of arrangement approved by 61,460,949 votes for, 501,355 against, 274,060 abstained.

• April 23, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01 ◈ Earnings Releases

  Kiniksa Q1 ARCALYST revenue $78.9M (+85% YoY); raises 2024 guidance to $370-390M

  ARCALYST net product revenue $78.9M in Q1 2024, up 85% YoY; total revenue $79.9M vs $48.3M in Q1 2023.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.90 · Median 0.65 · Most common event other_material

10 positive 0 negative 14 neutral

source · KNSA on sec.gov